Author (s) | Median CD4 count (cells/μl) | ART status | WHO stage IV (%) | Had headache (%) | + CrAg test, n (%) |
---|---|---|---|---|---|
Vidal et al. [28] | 25 | 74% on ART | 66 | No data | 5 (3.1) |
Ganiem et al. [29] | 20 | All naïve | no data | No data | 58 (7.1) |
Cheryl et al. [30] | 50 | All naïve | 36.2 | No data | 22 (5.8) |
Beyene et al. [31] | -* | 47.6% on ATR | 36.2 | 45.7 | 26 (10.2) |
Meya et al. [32] | 79 | All naïve | No data | 45.7 | 50 (8.2) |
Rugemalila et al. [33] | 96 | 44% on ART | No data | 66 | 7 (3) |
Longley et al. [34] | 55.5 | All naïve | No data | No data | 28 (4.3) |
Hailu et al. [35] | -** | 52% on ART | 45 | 33 | 9 (3.4) |
Letang et al. [36] | 71 | All naïve | No data | No data | 28 (3.7) |
Christopher et al. [37] | -*** | All on ART | No data | No data | 33 (9.9) |
Williams et al. [38] | 25 | 51% on ART | No data | No data | 149 (72)^ |
Alemu et al. [39] | 123 | 74% on ART | 100 | 28 | 31 (8.4) |
Derbie et al. [40] | 51.8 | All on ART | No data | No data | 16 (11.7) |
Mamuye et al. [41] | 93 | 51% on ART | 36% | 39 | 18 (9.1) |
Oyella et al. [42] | 23 | All naïve | No data | 37.1 | 69 (19) |
Ogouyemi et al. [18] | -** | All naïve | No data | No data | 6 (1.7) |
Drain et al. [43] | 75 | All naïve | No data | No data | 39 (9) |
Mdodo et al. [44] | 72 | 30.6% on ART | No data | 80.6 | 111 (33) |
Micol et al. [45] | 24 | All naïve | 28% | 52.5 | 59 (18) |
Jarvis et al. [46] | 97 | All naïve | No data | No data | 46 (7) |
Wajanga et al. [47] | 68 | All naïve | 17.9% | No data | 17 (5.1) |
Magambo et al. [48] | 97 | All naïve | 66 | 10 | 10 (7.1) |